{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:29Z","timestamp":1740107009528,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T00:00:00Z","timestamp":1613865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T00:00:00Z","timestamp":1613865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["QML20181101"],"award-info":[{"award-number":["QML20181101"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Municipal Administration of Hospitals Incubating Program","award":["PX2017042"],"award-info":[{"award-number":["PX2017042"]}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81672696"],"award-info":[{"award-number":["81672696"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals' Ascent Plan","doi-asserted-by":"crossref","award":["DFL20181101"],"award-info":[{"award-number":["DFL20181101"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00432-021-03563-0","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T16:02:26Z","timestamp":1613923346000},"page":"2731-2740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China"],"prefix":"10.1007","volume":"147","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZhiHong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiNan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LiLi","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BiXia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SiMing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XieQiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-0843","authenticated-orcid":false,"given":"ChuanLiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,21]]},"reference":[{"issue":"12","key":"3563_CR1","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/annonc\/mdw417","volume":"27","author":"KA Ahmed","year":"2016","unstructured":"Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ (2016) Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol 27(12):2288\u20132294. https:\/\/doi.org\/10.1093\/annonc\/mdw417","journal-title":"Ann Oncol"},{"issue":"1","key":"3563_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11060-014-1359-8","volume":"117","author":"A Alomari","year":"2014","unstructured":"Alomari A, Rauch PJ, Orsaria M, Minja FJ, Chiang VL, Vortmeyer AO (2014) Radiologic and histologic consequences of radiosurgery for brain tumors. J Neurooncol 117(1):33\u201342. https:\/\/doi.org\/10.1007\/s11060-014-1359-8","journal-title":"J Neurooncol"},{"issue":"4","key":"3563_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2217\/imt-2018-0149","volume":"11","author":"T Amaral","year":"2019","unstructured":"Amaral T, Tampouri I, Eigentler T, Keim U, Klumpp B, Heinrich V, Zips D, Paulsen F, Gepfner-Tuma I, Skardelly M, Tatagiba M, Tabatabai G, Garbe C, Forschner A (2019) Immunotherapy plus surgery\/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. Immunotherapy 11(4):297\u2013309. https:\/\/doi.org\/10.2217\/imt-2018-0149","journal-title":"Immunotherapy"},{"key":"3563_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000333","author":"T Amaral","year":"2020","unstructured":"Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, Gutzmer R, Haferkamp S, Uttikal J, Berking C, Rafei-Shamsabadi D, Reinhardt L, Meier F, Karoglan A, Posch C, Gambichler T, Pfoehler C, Thoms K, Tietze J, Debus D, Herbst R, Emmert S, Loquai C, Hassel JC, Meiss F, Tueting T, Heinrich V, Eigentler T, Garbe C, Zimmer L (2020) Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000333","journal-title":"J Immunother Cancer"},{"issue":"20","key":"3563_CR5","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1158\/1078-0432.CCR-17-0980","volume":"23","author":"X Bai","year":"2017","unstructured":"Bai X, Kong Y, Chi Z, Sheng X, Cui C, Wang X, Mao L, Tang B, Li S, Lian B, Yan X, Zhou L, Dai J, Guo J, Si L (2017) MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients: a retrospective study of 2,793 cases. Clin Cancer Res 23(20):6120\u20136127. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0980","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3563_CR6","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/ijc.28625","volume":"134","author":"KD Bishop","year":"2014","unstructured":"Bishop KD, Olszewski AJ (2014) Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. Int J Cancer 134(12):2961\u20132971. https:\/\/doi.org\/10.1002\/ijc.28625","journal-title":"Int J Cancer"},{"issue":"4","key":"3563_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","volume":"145","author":"PT Bradford","year":"2009","unstructured":"Bradford PT, Goldstein AM, McMaster ML, Tucker MA (2009) Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986\u20132005. Arch Dermatol 145(4):427\u2013434. https:\/\/doi.org\/10.1001\/archdermatol.2008.609","journal-title":"Arch Dermatol"},{"issue":"4","key":"3563_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1586\/ern.10.30","volume":"10","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain MC (2010) Brain metastases: a medical neuro-oncology perspective. Expert Rev Neurother 10(4):563\u2013573. https:\/\/doi.org\/10.1586\/ern.10.30","journal-title":"Expert Rev Neurother"},{"key":"3563_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2407-11-85","volume":"11","author":"Z Chi","year":"2011","unstructured":"Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J (2011) Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11:85. https:\/\/doi.org\/10.1186\/1471-2407-11-85","journal-title":"BMC Cancer"},{"issue":"20","key":"3563_CR10","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135\u20132147. https:\/\/doi.org\/10.1056\/NEJMoa050092","journal-title":"N Engl J Med"},{"issue":"8","key":"3563_CR11","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687\u20131696. https:\/\/doi.org\/10.1002\/cncr.25634","journal-title":"Cancer"},{"issue":"7","key":"3563_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Marquez-Rodas I, Del Vecchio M, Lebbe C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV (2017) Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863\u2013873. https:\/\/doi.org\/10.1016\/S1470-2045(17)30429-1","journal-title":"Lancet Oncol"},{"issue":"4","key":"3563_CR13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/annonc\/mdu577","volume":"26","author":"AM Di Giacomo","year":"2015","unstructured":"Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabro L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M (2015) Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol 26(4):798\u2013803. https:\/\/doi.org\/10.1093\/annonc\/mdu577","journal-title":"Ann Oncol"},{"issue":"7","key":"3563_CR14","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","volume":"22","author":"KM Fife","year":"2004","unstructured":"Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC, Besser M, Milton GW, McCarthy WH, Thompson JF (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22(7):1293\u20131300. https:\/\/doi.org\/10.1200\/JCO.2004.08.140","journal-title":"J Clin Oncol"},{"issue":"7","key":"3563_CR15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976\u2013983. https:\/\/doi.org\/10.1016\/S1470-2045(16)30053-5","journal-title":"Lancet Oncol"},{"issue":"10240","key":"3563_CR16","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Manikhas GM, Yan Y, Huang K-C, Uyei A, McNally V, McArthur GA, Ascierto PA (2020) Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 395(10240):1835\u20131844. https:\/\/doi.org\/10.1016\/S0140-6736(20)30934-X","journal-title":"Lancet"},{"issue":"9","key":"3563_CR17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1158\/2326-6066.CIR-18-0067","volume":"6","author":"JB Iorgulescu","year":"2018","unstructured":"Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, Aizer AA, Smith TR (2018) Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort. Cancer Immunol Res 6(9):1039\u20131045. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0067","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3563_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.2012.46.0410","volume":"31","author":"AJ Khan","year":"2013","unstructured":"Khan AJ, Dicker AP (2013) On the merits and limitations of whole-brain radiation therapy. J Clin Oncol 31(1):11\u201313. https:\/\/doi.org\/10.1200\/JCO.2012.46.0410","journal-title":"J Clin Oncol"},{"issue":"1","key":"3563_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.18.00204","volume":"37","author":"HM Kluger","year":"2019","unstructured":"Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB (2019) Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 37(1):52\u201360. https:\/\/doi.org\/10.1200\/JCO.18.00204","journal-title":"J Clin Oncol"},{"issue":"7","key":"3563_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","volume":"21","author":"D Kuk","year":"2016","unstructured":"Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, Ariyan CE, Brady MS, Coit DG, Bogatch K, Callahan MK, Wolchok JD, Carvajal RD, Postow MA (2016) Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist 21(7):848\u2013854. https:\/\/doi.org\/10.1634\/theoncologist.2015-0522","journal-title":"Oncologist"},{"issue":"6","key":"3563_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/ajco.12998","volume":"14","author":"R Ladwa","year":"2018","unstructured":"Ladwa R, Atkinson V (2018) The changing paradigm of management in melanoma brain metastases. Asia Pac J Clin Oncol 14(6):453\u2013458. https:\/\/doi.org\/10.1111\/ajco.12998","journal-title":"Asia Pac J Clin Oncol"},{"issue":"4","key":"3563_CR22","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/annonc\/mdw694","volume":"28","author":"B Lian","year":"2017","unstructured":"Lian B, Cui CL, Zhou L, Song X, Zhang XS, Wu D, Si L, Chi ZH, Sheng XN, Mao LL, Wang X, Tang BX, Yan XQ, Kong Y, Dai J, Li SM, Bai X, Zheng N, Balch CM, Guo J (2017) The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. Ann Oncol 28(4):868\u2013873. https:\/\/doi.org\/10.1093\/annonc\/mdw694","journal-title":"Ann Oncol"},{"issue":"11","key":"3563_CR23","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/s1470-2045(12)70431-x","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087\u20131095. https:\/\/doi.org\/10.1016\/s1470-2045(12)70431-x","journal-title":"Lancet Oncol"},{"issue":"9992","key":"3563_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/s0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandal\u00e0 M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (London, England) 386(9992):444\u2013451. https:\/\/doi.org\/10.1016\/s0140-6736(15)60898-4","journal-title":"Lancet (London, England)"},{"issue":"5","key":"3563_CR25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA (2018) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19(5):672\u2013681. https:\/\/doi.org\/10.1016\/S1470-2045(18)30139-6","journal-title":"Lancet Oncol"},{"issue":"5","key":"3563_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459\u2013465. https:\/\/doi.org\/10.1016\/S1470-2045(12)70090-6","journal-title":"Lancet Oncol"},{"issue":"5","key":"3563_CR27","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/cncr.20866","volume":"103","author":"CC McLaughlin","year":"2005","unstructured":"McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW (2005) Incidence of noncutaneous melanomas in the U.S. Cancer 103(5):1000\u20131007. https:\/\/doi.org\/10.1002\/cncr.20866","journal-title":"Cancer"},{"issue":"12","key":"3563_CR28","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","volume":"18","author":"AM Menzies","year":"2012","unstructured":"Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18(12):3242\u20133249. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0052","journal-title":"Clin Cancer Res"},{"key":"3563_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2018.12.023","volume":"110","author":"R Rauschenberg","year":"2019","unstructured":"Rauschenberg R, Bruns J, Br\u00fctting J, Daubner D, Lohaus F, Zimmer L, Forschner A, Zips D, Hassel JC, Berking C, Kaehler KC, Utikal J, Gutzmer R, Terheyden P, Meiss F, Rafei-Shamsabadi D, Kiecker F, Debus D, Dabrowski E, Arnold A, Garzarolli M, Kuske M, Beissert S, L\u00f6ck S, Linn J, Troost EGC, Meier F (2019) Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. Eur J Cancer 110:11\u201320. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.023","journal-title":"Eur J Cancer"},{"issue":"1","key":"3563_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","volume":"48","author":"L Si","year":"2012","unstructured":"Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, Guo J (2012) Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 48(1):94\u2013100. https:\/\/doi.org\/10.1016\/j.ejca.2011.06.056","journal-title":"Eur J Cancer"},{"issue":"4","key":"3563_CR31","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ijrobp.2017.06.2454","volume":"99","author":"PW Sperduto","year":"2017","unstructured":"Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M (2017) Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (Melanoma-molGPA). Int J Radiat Oncol Biol Phys 99(4):812\u2013816. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.06.2454","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"3563_CR32","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/sj.bjc.6605622","volume":"102","author":"M Staudt","year":"2010","unstructured":"Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, Tatagiba M, Brossart P, Garbe C (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102(8):1213\u20131218. https:\/\/doi.org\/10.1038\/sj.bjc.6605622","journal-title":"Br J Cancer"},{"issue":"8","key":"3563_CR33","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379(8):722\u2013730. https:\/\/doi.org\/10.1056\/NEJMoa1805453","journal-title":"N Engl J Med"},{"key":"3563_CR34","doi-asserted-by":"publisher","unstructured":"Tawbi HA-H, Forsyth PAJ, Hodi FS, Lao CD, Moschos SJ, Hamid O, Atkins MB, Lewis KD, Thomas RP, Glaspy JA, Jang S, Algazi AP, Khushalani NI, Postow MA, Pavlick AC, Ernstoff MS, Reardon DA, Balogh A, Rizzo JI, Margolin KA (2019) Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). 37(15_suppl):9501\u20139501. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.9501","DOI":"10.1200\/JCO.2019.37.15_suppl.9501"},{"issue":"4","key":"3563_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/pcmr.12682","volume":"31","author":"M Tio","year":"2018","unstructured":"Tio M, Wang X, Carlino MS, Shivalingam B, Fogarty GB, Guminski AD, Lo S, Hong AM, Menzies AM, Long GV (2018) Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. Pigment Cell Melanoma Res 31(4):509\u2013515. https:\/\/doi.org\/10.1111\/pcmr.12682","journal-title":"Pigment Cell Melanoma Res"},{"issue":"9","key":"3563_CR36","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1245\/s10434-020-08418-5","volume":"27","author":"X Wei","year":"2020","unstructured":"Wei X, Wu D, Li H, Zhang R, Chen Y, Yao H, Chi Z, Sheng X, Cui C, Bai X, Qi Z, Li K, Lan S, Chen L, Guo R, Yao X, Mao L, Lian B, Kong Y, Dai J, Tang B, Yan X, Wang X, Li S, Zhou L, Balch CM, Si L, Guo J (2020) The clinicopathological and survival profiles comparison across primary sites in acral melanoma. Ann Surg Oncol 27(9):3478\u20133485. https:\/\/doi.org\/10.1245\/s10434-020-08418-5","journal-title":"Ann Surg Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03563-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03563-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03563-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T10:08:47Z","timestamp":1627207727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03563-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,21]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["3563"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03563-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2021,2,21]]},"assertion":[{"value":"19 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors made no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}